Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32096839.
- Also identified by DOI 10.1001/jama.2020.0118 and PMC identifier PMC6583055.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study uses SECURE-PCI trial data to compare the effects of periprocedural loading doses of atorvastatin vs placebo on major adverse cardiac events (MACE) 12 months after randomization in patients with acute coronary syndrome (ACS) and planned invasive management.